Skye Bioscience Accounts Payable

Skye Bioscience (SKYE) currently reports a accounts payable of $3.9M as of March 2026. That compares with $1.7B in the prior-year period — down 99.8% year over year. Use the charts on this page to explore Skye Bioscience's accounts payable history and peer comparisons.

Skye Bioscience's accounts payable decreased from $1.7B to $3.9M — a 99.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Skye Bioscience reported $3.9M in accounts payable as of March 2026. That compares with $1.7B in the prior-year period — down 99.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $3.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Skye Bioscience, and consider following SKYE for alerts when major investors trade the stock.